MedPath

A real-world observational study evaluating efficacy and safety of neoadjuvant chemo-immunotherapy in patients with resectable non-small cell lung cancer (Neo FACT)

Not Applicable
Recruiting
Conditions
Resectable clinical stage IIA-IIIB non-small cell lung cancer receiving neoadjuvant chemo-immunotherapy
Registration Number
JPRN-UMIN000054053
Lead Sponsor
Hiroshima University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

For both Cohorts 1 and 2: 1. Patients deemed inappropriate by the principal investigator. 2. Patients under the age of 18 at the time of surgery.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath